Ampicillin/Gentamicin
Small molecule
Ampicillin/Gentamicin is one of 8 small molecule programs targeting Chorioamnionitis. It is currently in development.
1
Indications
2
Total Trials
0
Active Trials
7
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
11 competitors in Chorioamnionitis
#DrugCompanyPhaseTrials
1Garamycin
SSchering-Plough
Approved
Viramune
Boehringer IngelheimPhase 3
Flagyl
DDePuy Orthopaedics
Phase 3
E-Mycin
AAzurity Pharmaceuticals
Phase 3
Cysteine Hydrochloride
NovartisPhase 2
Unasyn
SStanford University
Phase 3
Ampicillin Sodium
UUniversity of Southern California
Phase 3
Ampicillin/Gentamicin
SStanford University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ampicillin/Gentamicin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Company
- SStanford University